|
Sections |
| Title | Starting Page | Number of Pages |
|---|
| Introduction to Datamonitor | 1 | 2 |
| CHAPTER GLOBAL MARKET ANALYSIS | 10 | 1 |
| 1.1 TREATMENT OF ASTHMA | 11 | 1 |
| 1.2 ASTHMA DRUG CLASS DEFINITIONS | 13 | 1 |
| ADVANTAGES | 13 | 1 |
| DISADVANTAGES | 14 | 2 |
| CORTICOSTEROIDS | 14 | 1 |
| ADVANTAGES | 15 | 7 |
| LEUKOTRIENE ANTAGONISTS | 15 | 2 |
| DISADVANTAGES | 17 | 5 |
| ANTICHOLINERGICS | 17 | 1 |
| MAST CELL INHIBITORS | 18 | 1 |
| XANTHINES | 19 | 1 |
| COMBINATION PRODUCTS | 20 | 1 |
| OTHERS | 20 | 1 |
| CLASS COMPARISONS | 21 | 2 |
| 1.3 ASTHMA MARKET ANALYSIS BY DRUG CLASS | 23 | 1 |
| OVERVIEW OF GLOBAL ASTHMA MARKET | 23 | 1 |
| TABLE: GLOBAL SALES OF DRUG CLASSES INDICATED FOR ASTHMA, 1998-99 | 23 | 1 |
| KEY TRENDS IN THE GLOBAL ASTHMA MARKET | 25 | 1 |
| TABLE: SALES GROWTH IN THE GLOBAL ASTHMA MARKET BY DRUG CLASS, 1995-99 | 25 | 1 |
| CLASS GROWTH ANALYSIS | 27 | 1 |
| TABLE: FACTORS AFFECTING DRUG CLASS GROWTH, 1995-99 | 27 | 1 |
| 1.4 Beta2 Agonists | 28 | 1 |
| Overview Of The Global Beta (2) Agonist Market | 29 | 3 |
| Table: Global Sales Of The Leading Branded Beta2 Agonist Drugs, 1998-99 | 29 | 1 |
| Table: Summary Of Beta (2) Agonist Drug SWOT analyses | 31 | 1 |
| Key Trends In The Global Beta2 Agonist Market | 32 | 1 |
| Table: Sales Growth In The Beta2 Agonist Market, 1995-99 | 32 | 1 |
| SEREVENT (SALMETEROL XINAFOATE) | 33 | 1 |
| TABLE: SEREVENT'S PROFILE | 33 | 1 |
| SWOT Analysis | 34 | 1 |
| VENTOLIN (SALBUTAMOL, ALBUTEROL) | 36 | 1 |
| TABLE: VENTOLIN'S PROFILE | 36 | 1 |
| SWOT Analysis | 36 | 2 |
| PROVENTIL (SALBUTAMOL) | 39 | 1 |
| TABLE: PROVENTIL'S PROFILE | 39 | 1 |
| SWOT Analysis | 39 | 3 |
| FORADIL (FORMOTEROL) | 41 | 1 |
| TABLE: FORADIL'S PROFILE | 41 | 1 |
| 1.5 CORTICOSTEROIDS | 43 | 1 |
| TABLE: CORTICOSTEROID'S PROFILE | 43 | 1 |
| OVERVIEW OF THE GLOBAL CORTICOSTEROID MARKET | 44 | 3 |
| TABLE: GLOBAL SALES OF THE LEADING BRANDED CORTICOSTEROID DRUGS, 1998-99 | 44 | 1 |
| Table: Summary Of Corticosteroid Drug SWOT Analyses | 46 | 1 |
| KEY TRENDS IN THE GLOBAL CORTICOSTEROID MARKET | 46 | 2 |
| TABLE: SALES GROWTH IN THE CORTICOSTEROID MARKET, 1995-99 | 46 | 1 |
| FLIOXTIDE/FLOVENT (FLUTICASONE) | 48 | 1 |
| TABLE: FLOVENT'S PROFILE | 48 | 1 |
| SWOT Analysis | 48 | 2 |
| PULMICORT (BUDESONIDE) | 51 | 1 |
| TABLE: PULMICORT'S PROFILE | 51 | 1 |
| SWOT Analysis | 51 | 1 |
| 1.6 LEUKOTRIENE ANTAGONISTS | 53 | 1 |
| TABLE: LEUKOTRIENE ANTAGONISTS PROFILE | 53 | 1 |
| OVERVIEW OF THE GLOBAL LEUKOTRIENE ANTAGONIST MARKET | 53 | 3 |
| TABLE: GLOBAL SALES OF THE LEADING BRANDED LEUKOTRIENE ANTAGONIST DRUGS, 1998-99 | 53 | 1 |
| Table: Summary Of LAS Drug SWOT Analyses | 55 | 1 |
| KEY TRENDS IN THE GLOBAL LEUKOTRIENE ANTAGONIST MARKET | 55 | 2 |
| TABLE: SALES GROWTH IN THE LEUKOTRIENE ANTAGONIST MARKET, 1995-99 | 55 | 1 |
| SINGULAIR (MONTELUKAST) | 56 | 1 |
| TABLE: SINGULAIR'S PROFILE | 56 | 1 |
| SWOT Analysis | 57 | 1 |
| ACCOLATE (ZAFIRLUKAST) | 58 | 1 |
| TABLE: ACCOLATE'S PROFILE | 58 | 1 |
| SWOT Analysis | 59 | 1 |
| 1.7 ANTICHOLINERGICS | 61 | 1 |
| TABLE: ANTICHOLINERGICS PROFILE | 61 | 1 |
| OVERVIEW OF THE GLOBAL ANTICHOLINERGICS MARKET | 61 | 2 |
| TABLE: GLOBAL SALES OF THE LEADING BRANDED ANTICHOLINERGIC DRUGS, 1998-99 | 61 | 1 |
| Table: Summary Of Anticholinergic Drug SWOT Analyses | 62 | 1 |
| KEY TRENDS IN THE GLOBAL ANTICHOLINERGIC MARKET | 63 | 1 |
| Table: Sales Growth In The Anticholinergic Market, 1995-99 | 63 | 1 |
| ATROVENT (IPRATROPIUM BROMIDE) | 64 | 1 |
| TABLE: ATROVENT'S PROFILE | 64 | 1 |
| SWOT Analysis | 65 | 1 |
| 1.8 XANTHINES | 67 | 1 |
| TABLE: XANTHINES PROFILE | 67 | 1 |
| OVERVIEW OF THE GLOBAL XANTHINES MARKET | 67 | 2 |
| TABLE: GLOBAL SALES OF THE LEADING BRANDED XANTHINE DRUGS, 1998-99 | 67 | 1 |
| Table: Summary Of Xanthine Drug SWOT Analyses | 69 | 1 |
| KEY TRENDS IN THE GLOBAL XANTHINE MARKET | 69 | 2 |
| TABLE: SALES GROWTH IN THE XANTHINE MARKET, 1995-99 | 69 | 1 |
| THEODUR (THEOPHYLLINE) | 71 | 1 |
| Table: Theo-Dur's Profile | 71 | 1 |
| SWOT Analysis | 71 | 2 |
| 1.9 MAST CELL INHIBITORS | 73 | 1 |
| TABLE: MAST CELL INHIBITORS PROFILE | 73 | 1 |
| OVERVIEW OF THE GLOBAL MAST CELL INHIBITOR MARKET | 73 | 2 |
| TABLE: GLOBAL SALES OF THE LEADING BRANDED MAST CELL INHIBITOR DRUGS, 1998-99 | 73 | 1 |
| Table: Summary Of Mast Cell Inhibitor Drug SWOT Analyses | 74 | 1 |
| KEY TRENDS IN THE GLOBAL MAST CELL INHIBITOR MARKET | 75 | 1 |
| TABLE: SALES GROWTH IN THE MAST CELL INHIBITOR MARKET, 1995-99 | 75 | 1 |
| INTAL (SODIUM CROMOGLYCATE) | 76 | 1 |
| TABLE: INTAL'S PROFILE | 76 | 1 |
| SWOT Analysis | 77 | 1 |
| 1.10 COMBINATION DRUGS | 79 | 1 |
| TABLE: COMBINATION DRUGS PROFILE | 79 | 1 |
| OVERVIEW OF THE GLOBAL COMBINATION DRUGS MARKET | 79 | 1 |
| TABLE: GLOBAL SALES OF THE LEADING BRANDED COMBINATION DRUGS, 1998-99 | 79 | 1 |
| SERETIDE (FLUTICASONE, SALMETEROL) | 80 | 1 |
| TABLE: SERETIDE'S PROFILE | 80 | 1 |
| SWOT Analysis | 80 | 1 |
| 1.11 OTHERS | 82 | 1 |
| Table: Profile Of 'Other' Drugs | 82 | 1 |
| OVERVIEW OF THE GLOBAL OTHER DRUGS MARKET | 82 | 2 |
| TABLE: GLOBAL SALES OF THE LEADING BRANDED OTHER DRUGS, 1998-99 | 82 | 1 |
| Table: Summary Of 'Other' Drugs SWOT Analyses | 83 | 1 |
| Key Trends In The Global 'Other' Drugs Market | 84 | 1 |
| TABLE: SALES GROWTH IN THE OTHER DRUGS MARKET, 1995-99 | 84 | 1 |
| ZADITEN (KETOTIFEN) | 86 | 1 |
| TABLE: ZADITEN'S PROFILE | 86 | 1 |
| SWOT Analysis | 86 | 1 |
